One-Time DNA Study for Vasculitis
| Tracking Information | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | October 22, 2010 | ||||||||||||||||||||||||||||||||||||||||
| Last Updated Date | October 23, 2012 | ||||||||||||||||||||||||||||||||||||||||
| Start Date ICMJE | October 2010 | ||||||||||||||||||||||||||||||||||||||||
| Estimated Primary Completion Date | August 2014 (final data collection date for primary outcome measure) | ||||||||||||||||||||||||||||||||||||||||
| Current Primary Outcome Measures ICMJE |
Evaluation of clinical data and linked DNA specimens. [ Time Frame: 1 year. ] [ Designated as safety issue: No ] | ||||||||||||||||||||||||||||||||||||||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||||||||||||||||||||||||||||||
| Change History | Complete list of historical versions of study NCT01241305 on ClinicalTrials.gov Archive Site | ||||||||||||||||||||||||||||||||||||||||
| Current Secondary Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||||||||||||||||||||||
| Original Secondary Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||||||||||||||||||||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||||||||||||||||||||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||||||||||||||||||||||
| Descriptive Information | |||||||||||||||||||||||||||||||||||||||||
| Brief Title ICMJE | One-Time DNA Study for Vasculitis | ||||||||||||||||||||||||||||||||||||||||
| Official Title ICMJE | VCRC Genetic Repository One-Time DNA Protocol | ||||||||||||||||||||||||||||||||||||||||
| Brief Summary | The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases. |
||||||||||||||||||||||||||||||||||||||||
| Detailed Description | The systemic vasculitides comprise several inflammatory diseases of blood vessels, usually arteries, which may cause systemic, multi-organ disease that can result in substantial morbidity and increased mortality. Each type of vasculitis is a rare ("orphan") disease. However, taken together, vasculitis affects tens of thousands of Americans and is responsible for substantial morbidity and mortality and almost one billion dollars per year in hospital care alone. While the vasculitides share the trait of vascular inflammation, the unique disease phenotypes, clinical courses, differences in prognoses, and responses to therapy suggest that important differences exist in pathogenesis. The Vasculitis Clinical Research Consortium (VCRC) currently focuses on 6 specific types of vasculitis that were selected to represent a balance between unmet medical and scientific needs, prevalence in North America, feasibility of study, and an interest in studying a spectrum of small, medium, and large vessel vasculitides. The great majority of published studies on the genetics of vasculitis have used modest-sized cohorts that are only suitable for investigation of a few candidate genes at a time, or to detect large effect sizes, so that replicated findings are highly skewed to the HLA region. Larger and more ambitious genetic studies in vasculitis are expected to generate numerous hypotheses for translational research in gene expression, biochemistry, and molecular pathology. A one-time collection of clinical data and DNA would substantially increase the sample sizes for genetic association studies in all six vasculitides studied in the VCRC. Many patients are seen at participating VCRC centers but do not enroll in the Longitudinal Studies. These patients often are interested in participating in research studies but cannot return frequently for visits, usually due to distance from the VCRC centers. This approach would be particularly useful for the rarer forms of vasculitis under study (Takayasu's Arteritis (TAK), Polyarteritis Nodosa (PAN), Churg-Strauss Syndrome (CSS) and also for Giant Cell Arteritis (GCA), since elderly patients have been particularly likely to decline participation in the Longitudinal Studies due to travel constraints. |
||||||||||||||||||||||||||||||||||||||||
| Study Type ICMJE | Observational | ||||||||||||||||||||||||||||||||||||||||
| Study Design ICMJE | Observational Model: Cohort Time Perspective: Prospective |
||||||||||||||||||||||||||||||||||||||||
| Target Follow-Up Duration | Not Provided | ||||||||||||||||||||||||||||||||||||||||
| Biospecimen | Retention: Samples With DNA Description: Two 10 ml tubes of blood will be collected for DNA extraction. |
||||||||||||||||||||||||||||||||||||||||
| Sampling Method | Non-Probability Sample | ||||||||||||||||||||||||||||||||||||||||
| Study Population | Individuals with giant cell arteritis, Takayasu's arteritis, polyarteritis nodosa, granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, and Churg-Strauss syndrome. Enrollment will be sequential and patients will have disease in various stages and of different duration. |
||||||||||||||||||||||||||||||||||||||||
| Condition ICMJE |
|
||||||||||||||||||||||||||||||||||||||||
| Intervention ICMJE | Not Provided | ||||||||||||||||||||||||||||||||||||||||
| Study Group/Cohort (s) | Not Provided | ||||||||||||||||||||||||||||||||||||||||
| Publications * | Not Provided | ||||||||||||||||||||||||||||||||||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||||||||||||||||||||||||||
| Recruitment Information | |||||||||||||||||||||||||||||||||||||||||
| Recruitment Status ICMJE | Recruiting | ||||||||||||||||||||||||||||||||||||||||
| Estimated Enrollment ICMJE | 1300 | ||||||||||||||||||||||||||||||||||||||||
| Estimated Completion Date | August 2014 | ||||||||||||||||||||||||||||||||||||||||
| Estimated Primary Completion Date | August 2014 (final data collection date for primary outcome measure) | ||||||||||||||||||||||||||||||||||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria: 1. Diagnostic criteria for Giant Cell Arteritis Age at disease onset >50 years (required)
2. Diagnostic criteria for Takayasu's Arteritis
3. Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other causes) felt by investigator to be due to vasculitis
Minor criteria (not explained by other causes) felt by investigator to be due to vasculitis
Isolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN 4. Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangitis (MPA)
|
||||||||||||||||||||||||||||||||||||||||
| Gender | Both | ||||||||||||||||||||||||||||||||||||||||
| Ages | 7 Years and older | ||||||||||||||||||||||||||||||||||||||||
| Accepts Healthy Volunteers | No | ||||||||||||||||||||||||||||||||||||||||
| Contacts ICMJE |
|
||||||||||||||||||||||||||||||||||||||||
| Location Countries ICMJE | United States, Canada | ||||||||||||||||||||||||||||||||||||||||
| Administrative Information | |||||||||||||||||||||||||||||||||||||||||
| NCT Number ICMJE | NCT01241305 | ||||||||||||||||||||||||||||||||||||||||
| Other Study ID Numbers ICMJE | RDCRN 5510, U54AR057319-06 | ||||||||||||||||||||||||||||||||||||||||
| Has Data Monitoring Committee | Yes | ||||||||||||||||||||||||||||||||||||||||
| Responsible Party | Peter Merkel, University of Pennsylvania | ||||||||||||||||||||||||||||||||||||||||
| Study Sponsor ICMJE | University of Pennsylvania | ||||||||||||||||||||||||||||||||||||||||
| Collaborators ICMJE |
|
||||||||||||||||||||||||||||||||||||||||
| Investigators ICMJE |
|
||||||||||||||||||||||||||||||||||||||||
| Information Provided By | University of Pennsylvania | ||||||||||||||||||||||||||||||||||||||||
| Verification Date | October 2012 | ||||||||||||||||||||||||||||||||||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||||||||||||||||||||||||||||||||||